A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.

@article{Li2011ACS,
  title={A comparative study of paliperidone palmitate and risperidone long-acting injectable therapy in schizophrenia.},
  author={Huafang Li and Qing Rui and Xiaoping Ning and Haiyan Xu and Niufan Gu},
  journal={Progress in neuro-psychopharmacology & biological psychiatry},
  year={2011},
  volume={35 4},
  pages={1002-8}
}
This open-label, rater-blinded, parallel-group study was designed to evaluate noninferiority of paliperidone palmitate (PP), a once-monthly injectable atypical antipsychotic, to once-biweekly risperidone long-acting injectable (RIS-LAI) in adult Chinese patients with acute schizophrenia. Eligible Chinese adults (N=452) with schizophrenia were randomized (1:1) to either PP (N=229; deltoid injections on day 1 [150 mg eq.] and day 8 [100 mg eq.]; then once-monthly deltoid or gluteal injections… CONTINUE READING